We serve Chemical Name:2-(2-bromopyridin-3-yl)oxyacetic acid CAS:118650-04-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-(2-bromopyridin-3-yl)oxyacetic acid
CAS.NO:118650-04-7
Synonyms:2-(2-bromopyridin-3-yl)oxyacetic acid
Molecular Formula:C7H6BrNO3
Molecular Weight:232.03100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:59.42000
Exact Mass:230.95300
LogP:1.30750
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-(2-bromopyridin-3-yl)oxyacetic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-(2-bromopyridin-3-yl)oxyacetic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-(2-bromopyridin-3-yl)oxyacetic acid Use and application,2-(2-bromopyridin-3-yl)oxyacetic acid technical grade,usp/ep/jp grade.
Related News: The intravenous form of rigosertib has been studied in Phase 1, 2, and 3 clinical trials involving more than 1000 patients, and is currently being evaluated in a randomized Phase 3 international INSPIRE trial for patients with HR-MDS after failure of HMA therapy. 2-(2-bromopyridin-3-yl)oxyacetic acid manufacturer This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. 2-(2-bromopyridin-3-yl)oxyacetic acid supplier This decision has shaken the foundations of the scientific process and methods, said Dr. Jason Karlawish, co-director of the Penn Memory Center in Philadelphia. Karlawish ran one of the trial sites for the Biogen drug. 2-(2-bromopyridin-3-yl)oxyacetic acid vendor The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement. 2-(2-bromopyridin-3-yl)oxyacetic acid factory The entire set of results “strongly support” the Darzalex-Rd combo as a new standard of care for newly diagnosed, transplant-ineligible multiple myeloma patients, Thierry Facon, M.D., an investigator of the MAIA trial, said in a statement.
